A combination therapy that adds a recently approved drug to the current standard of care for newly diagnosed acute myeloid ...

A combination therapy that adds a recently approved drug to the current standard of care for newly diagnosed acute myeloid ...

Revumenib shows promise for high-risk patients with acute myeloid leukemia (AML) with specific genetic mutations, ...

Congress, Ashley Yocum, PhD, highlights how the Beat AML Master Trial advances safe, personalized treatment and expands targeted therapy options for patients with acute myeloid leukemia (AML).

Robust responses observed across subgroups, regardless of co-mutations, number of prior lines of therapy, or prior venetoclax, within efficacy-evaluable pivotal R/R mNPM1 AML population – – 60% (3/5) ...

Revumenib was generally well-tolerated in combination with venetoclax/azacitidine in older, newly diagnosed mNPM1 and KMT2Ar AML patients – – Promising clinical activity and deep responses observed ...

Adding the menin inhibitor revumenib (Revuforj) to azacitidine and venetoclax (Venclexta) seemed to benefit older adults with ...

Join Drs Tania Jain and Rachel Salit as they explore evolving definitions of remission, relapse monitoring, and ...